Developments Myovant’s relugolix meets primary endpoint in Phase 3 uterine fibroid trial Myovant Sciences (NASDAQ:MYOV) reported that the second of two Phase 3 studies of relugolix met its primary efficacy endpoint and six key secondary endpoints in women with uterine fibroids. Relugolix is a once daily... July 24, 2019